[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100630092":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":31,"locations":37,"responsibleParty":56,"collaborators":11,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":11,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":11,"enrollmentInfo":67,"targetDuration":11,"studyType":70,"phases":71,"briefSummary":74,"conditions":75,"keywords":77,"overallStatus":40,"whyStopped":11,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Mayo Clinic","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Spironolactone","EXPERIMENTAL",null,[13],"Drug: Spironolactone",{"label":15,"type":16,"description":11,"interventionNames":17},"Placebo","PLACEBO_COMPARATOR",[18],"Drug: Placebo",[20,24],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":11},"DRUG","Subjects will receive spironolactone 25 mg once daily for the first 4 weeks, followed by an increased dose of 50 mg once daily for an additional 5 months.",[9],{"type":21,"name":15,"description":25,"armGroupLabels":26,"otherNames":11},"Subjects will receive 25 mg of the placebo once daily for the first 4 weeks, followed by an increased dose of 50 mg once daily for an additional 5 months.",[15],[28],{"name":29,"affiliation":5,"role":30},"Thais Coutinho","PRINCIPAL_INVESTIGATOR",[32],{"name":33,"role":34,"phone":35,"phoneExt":11,"email":36},"Saad Omar","CONTACT","507-538-5162","omar.saad@mayo.edu",[38],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Mayo Clinic in Rochester","RECRUITING","Rochester","Minnesota","55905","United States","US",{"type":47,"coordinates":48},"Point",[49,50],-92.4699,44.02163,{"lat":50,"lon":49},[53,54],{"name":33,"role":34,"phone":35,"phoneExt":11,"email":11},{"name":55,"role":30,"phone":11,"phoneExt":11,"email":11},"Thais D Coutinho",{"type":30,"investigatorFullName":29,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"Principal Investigator","100630092","phase-1-heart-pilot-randomized-controlled-trial-100630092",false,"NCT07483177","HEART: Pilot Randomized Controlled Trial","Hemodynamic Effects Of Aldosterone Receptor Blockade In Degenerative Thoracic Aortic Aneurysm: A Pilot Randomized Controlled Trial (HEART: Pilot RCT)","Inclusion Criteria\n\n1. Adults ≥ 18 years old with dTAA of the aortic root and\u002For ascending aorta exceeding the upper limit of normal for age, sex, and body surface area (≥ 4.0 cm as an example of a common threshold; but age, sex and body size-specific thresholds have been established for the aortic root24 and ascending aorta25);\n2. no antihypertensive use or stable antihypertensive regimen ≥ 4 weeks;\n3. eGFR ≥ 50 mL\u002Fmin\u002F1.73 m²;\n4. serum potassium ≤ 5.1 mmol\u002FL;\n5. ability to provide informed consent.\n\nExclusion Criteria\n\n1. Heritable aortopathies (Marfan, Loeys-Dietz, vascular Ehlers-Danlos, Turner syndromes; familial TAA, genetically-proven TAA);\n2. bicuspid aortic valve;\n3. inflammatory aortitis,\n4. prior aortic surgery, endovascular repair, or acute aortic syndrome;\n5. permanent atrial fibrillation\u002Fflutter;\n6. major peripheral artery disease affecting the carotids, iliacs and\u002For external femoral arteries precluding cfPWV measurement;\n7. current use of spironolactone, eplerenone or finererone;\n8. pregnancy or lactation.","ALL","18 Years",{"count":68,"type":69},50,"ESTIMATED","INTERVENTIONAL",[72,73],"PHASE1","PHASE2","The purpose of this study is to determine whether spironolactone reduces aortic stiffness, measured by carotid-femoral pulse wave velocity (cfPWV), compared with placebo, in patients with degenerative thoracic aortic aneurysms.",[76],"Thoracic Aortic Aneurysm",[78,79,80,81,82],"spironolactone","aortic aneurysm","thoracic aortic aneurysm","aortic stiffness","arterial stiffness","2026-06-04",{"date":85,"type":86},"2026-06-08","ACTUAL",{"date":88,"type":86},"2026-05-25",{"date":90,"type":69},"2028-05",{"name":5,"class":6},1]